Abstracts tagged "gout"

Abstract Number: 2289 • 2016 ACR/ARHP Annual Meeting
Obesity and Echocardiographic Changes in the Different Stages of Gout
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov¹, ¹Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose: Studies on gout and its stages as a cardiovascular (CV) risk factor are few and with contradictory results. We compared echocardiographic parameters, known as…
Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Masanari Shiramoto¹, Masatoshi Sugeno², Sha Liu³, Zangong Shen³ and Jesse Hall³, ¹SOUSEIKAI PS Clinic, Fukuoka, Japan, ²AstraZeneca K.K., Osaka, Japan, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…
Abstract Number: 226 • 2016 ACR/ARHP Annual Meeting
Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA
Puja Khanna¹, Eskinder Tafesse², Scott Baumgartner³, Anna Walker⁴ and Robert Morlock³, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²AstraZeneca Pharmaceuticals, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA, ⁴AstraZeneca Pharmaceuticals, Luton, United Kingdom
Background/Purpose: Less than 30% of gout patients achieve treatment targets and patients with tophi are less likely to achieve these goals than patients without tophi.…
Abstract Number: 2295 • 2016 ACR/ARHP Annual Meeting
A Non-Linear Relationship Between Physical Activity and Serum Uric Acid Concentrations: Nhanes 2003-2004
Nicholas Holdgate¹, Carl Pieper^2,3, Tony Ning⁴, William E. Kraus^5,6 and Kim Huffman^1,5, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, ³Biostatistics and Bioinformatics, Duke Pepper Center, Durham, NC, ⁴Triangle Orthopedic Associates, Durham, NC, ⁵Duke Pepper Center, Durham, NC, ⁶Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Hyperuricemia is a known cardio-metabolic risk factor as well as risk factor for gout. Physical activity has been found to improve many other cardio-metabolic…
Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Xiaohong Yan³, Jeffrey N. Miner^3,4, Liz Hicks³, Shakti Valdez³ and Martha Hernandez-Illas⁵, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁵QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 227 • 2016 ACR/ARHP Annual Meeting
Inadequately Treated Chronic Gout As the Main Reason for Primary Gout Admission in an Urban Adult Population: Results of a Retrospective Cohort Study
Mandissa Sealey¹, Ibrahim Barry², Tanyka Sam¹, Olakanmi Awe¹ and Stuart Green³, ¹Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, ²Internal Medicine, The Brooklyn Hospital Center, Bronx, NY, ³Internal Medicine, The Brooklyn Hospital Center, Larchmont, NY
Background/Purpose: Inadequately treated patients with chronic gout are at risk for an acute attack and many often require hospitalization. An acute attack of gout increases…
Abstract Number: 2296 • 2016 ACR/ARHP Annual Meeting
The Influence of Androgen Deprivation Therapy on Serum Uric Acid Level
Jae Hyun Lee¹, Eun Hye Park², Sang Wan Chung³, Jaehyung Hur³, You Jung Ha³, Yeong Wook Song^1,4 and Yun Jong Lee^5,6, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: The prevalence of hyperuricemia and gout suggests that sex hormones play a role in the gender difference with gout. Estrogen has been thought to…
Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Shakti Valdez³, Sha Liu³, Xiaohong Yan³, Liz Hicks³ and Martha Hernandez-Illas⁴, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 229 • 2016 ACR/ARHP Annual Meeting
Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population
Michael Pillinger¹, Svetlana Krasnokutsky Samuels¹, Raymond Malamet², Bruce Schechter², Douglas CA Taylor³ and Robert Morlock⁴, ¹New York University, New York, NY, ²AstraZeneca, Gaithersburg, MD, ³Ironwood Pharmaceuticals, Cambridge, MA, ⁴Ardea Biosciences, Inc., San Diego, CA
Background/Purpose : Gout is the most prominent clinical manifestation of hyperuricemia, and is the most common cause of inflammatory arthritis. The symptoms of gout (eg,…
Abstract Number: 2298 • 2016 ACR/ARHP Annual Meeting
Incident Risk of Acute Gout Among Active Smokers: Data from Nationwide Inpatient Sample
Dilli Poudel¹, Paras Karmacharya¹ and Anthony Donato², ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA
Background/Purpose: Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous anti-oxidant…
Abstract Number: 204 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate lowering therapy. Many patients on allopurinol fail to achieve target serum urate (SU), in part due to…
Abstract Number: 1013 • 2016 ACR/ARHP Annual Meeting
The Risk of Colchicine Associated Myopathy in Gout: Influence of Concomitant Use of Statin
Oh Chan Kwon¹, Byeongzu Ghang², Seokchan Hong³, Yong-Gil Kim⁴, Chang-Keun Lee³ and Bin Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan Collage of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: To investigate the risk of concomitant use of statin on the development of myopathy in gout patients who received colchicine. Methods: We included patients…
Abstract Number: 2299 • 2016 ACR/ARHP Annual Meeting
Predictors of Mortality in People with Recent Onset of Gout: A Prospective Observational Study
Zoe Vincent¹, Gregory Gamble², Meaghan House², Julie Knight¹, Anne Horne², William J. Taylor³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand
Background/Purpose: Many studies have reported that gout is associated with increased risk of cardiovascular events and mortality. However, information regarding gout disease severity is limited…
Abstract Number: 206 • 2016 ACR/ARHP Annual Meeting
Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies
Robert Terkeltaub¹, Raymond Malamet², Kathleen Bos², Jingyi Li², David Goldfarb³, Michael Pillinger⁴, Diana Jalal⁵, Jia Hu⁶ and Kenneth Saag⁷, ¹Rheumatology, VA Medical Center, San Diego, CA, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³New York University School of Medicine, New York, NY, USA, New York, NY, ⁴Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁵University of Colorado Anschutz Medical Center, Aurora, CO, USA, Aurora, CO, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor approved in the United States and European Union at 200 mg daily dose in combination with…
Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting
Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis
Ji Eun Song¹, Ji Hye Shin¹, Ki Won Moon², Se Hui Shon¹, Ji Soo Park³, Eun Bong Lee³, Yeong Wook Song^1,3 and Eun Young Lee³, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ²Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of
Background/Purpose: Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].